{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:04:21Z","timestamp":1793239461667,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12020-020-02426-x","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T10:03:36Z","timestamp":1595239416000},"page":"434-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2900-2099","authenticated-orcid":false,"given":"Helton Estrela","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Berdelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"2426_CR1","doi-asserted-by":"publisher","first-page":"R499","DOI":"10.1530\/ERC-18-0574","volume":"26","author":"L Ceolin","year":"2019","unstructured":"L. Ceolin, M.A. Duval, S. da, A.F. Benini, C.V. Ferreira, A.L. Maia, Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr. Relat. Cancer 26, R499\u2013518 (2019)","journal-title":"Endocr. Relat. Cancer"},{"key":"2426_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"S.A. Wells et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134\u2013141 (2012)","journal-title":"J. Clin. Oncol."},{"key":"2426_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.beem.2017.04.009","volume":"31","author":"J Hadoux","year":"2017","unstructured":"J. Hadoux, M. Schlumberger, Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 31, 335\u2013347 (2017)","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"2426_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","volume":"31","author":"C Resteghini","year":"2017","unstructured":"C. Resteghini et al. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract. Res. Clin. Endocrinol. Metab. 31, 349\u2013361 (2017)","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"2426_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1089\/thy.2014.0361","volume":"25","author":"CN Chougnet","year":"2015","unstructured":"C.N. Chougnet et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a french cohort. Thyroid 25, 386\u2013391 (2015)","journal-title":"Thyroid"},{"key":"2426_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ecl.2018.11.006","volume":"48","author":"D Viola","year":"2019","unstructured":"D. Viola, R. Elisei, Management of medullary thyroid cancer. Endocrinol. Metab. Clin. N. Am. 48, 285\u2013301 (2019)","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"2426_CR7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"M.E. Cabanillas, M. Ryder, C. Jimenez, Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev. 40, 1573\u20131604 (2019)","journal-title":"Endocr. Rev."},{"key":"2426_CR8","doi-asserted-by":"publisher","unstructured":"S.R. Priya, C.S. Dravid, R. Digumarti, M. Dandekar, Targeted therapy for medullary thyroid cancer: a review. Front. Oncol. 7, 238 (2017). https:\/\/doi.org\/10.3389\/fonc.2017.00238","DOI":"10.3389\/fonc.2017.00238"},{"key":"2426_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-017-0041-6","volume":"10","author":"G Geller","year":"2017","unstructured":"G. Geller, J. Laskin, W.Y. Cheung, C. Ho, A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res. 10, 6 (2017)","journal-title":"Thyroid Res."},{"key":"2426_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jmedgenet-2016-103833","volume":"53","author":"C Romei","year":"2016","unstructured":"C. Romei et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J. Med. Genet. 53, 729\u2013734 (2016)","journal-title":"J. Med. Genet."},{"key":"2426_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/cen.12686","volume":"82","author":"C Romei","year":"2015","unstructured":"C. Romei et al. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Clin. Endocrinol. 82, 892\u2013899 (2015)","journal-title":"Clin. Endocrinol."},{"key":"2426_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-19-0259","volume":"27","author":"L Valerio","year":"2020","unstructured":"L. Valerio et al. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. Endocr. Relat. Cancer 27, 97\u2013110 (2020)","journal-title":"Endocr. Relat. Cancer"},{"key":"2426_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bcp.12149","volume":"76","author":"W-X Qi","year":"2013","unstructured":"W.-X. Qi, A.-N. He, Z. Shen, Y. Yao, Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 76, 348\u2013357 (2013)","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2426_CR14","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.3390\/ijms19103258","volume":"19","author":"R Milling","year":"2018","unstructured":"R. Milling et al. Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int. J. Mol. Sci. 19, 3258 (2018)","journal-title":"Int. J. Mol. Sci."},{"key":"2426_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ctrv.2018.04.007","volume":"66","author":"MS Brose","year":"2018","unstructured":"M.S. Brose et al. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat. Rev. 66, 64\u201373 (2018)","journal-title":"Cancer Treat. Rev."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02426-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02426-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:31:02Z","timestamp":1626741062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02426-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02426-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"15 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.S. and S.L. have attended advisory boards for Astra Zeneca. M.S. received research funding from Astra Zeneca, Amgen, Exelixis, Bayer, and Eisai. The other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent has been obtained from all the patients for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}